Robert Anders (Q44468): Difference between revisions
From geokb
(Changed an Item: Added ORCID identifier to person item from scrape of USGS Staff Profile page) |
(Changed an Item: updated qualifiers for official website claim from latest USGS Staff Profile cache) |
||||||||||||||
| (16 intermediate revisions by the same user not shown) | |||||||||||||||
| label / en | label / en | ||||||||||||||
Robert Anders | Robert Anders | ||||||||||||||
| aliases / en / 0 | aliases / en / 0 | ||||||||||||||
Robert Anders | |||||||||||||||
| aliases / en / 1 | aliases / en / 1 | ||||||||||||||
Robert Albert Anders | |||||||||||||||
| aliases / en / 2 | aliases / en / 2 | ||||||||||||||
R. Anders | |||||||||||||||
| aliases / en / 3 | aliases / en / 3 | ||||||||||||||
Robert A. Anders | |||||||||||||||
| aliases / en / 4 | aliases / en / 4 | ||||||||||||||
R. A. Anders | |||||||||||||||
| description / en | description / en | ||||||||||||||
Research Hydrologist | Research Hydrologist with the California Water Science Center | ||||||||||||||
| Property / instance of: person / reference | |||||||||||||||
| Property / employer | |||||||||||||||
| Property / employer: United States Geological Survey / rank | |||||||||||||||
| Property / employer: United States Geological Survey / qualifier | |||||||||||||||
| |||||||||||||||
| Property / employer: United States Geological Survey / reference | |||||||||||||||
| Property / reference URL | |||||||||||||||
| Property / reference URL: https://www.usgs.gov/staff-profiles/robert-anders / rank | |||||||||||||||
| Property / reference URL: https://www.usgs.gov/staff-profiles/robert-anders / qualifier | |||||||||||||||
| |||||||||||||||
| Property / reference URL: https://www.usgs.gov/staff-profiles/robert-anders / reference | |||||||||||||||
| Property / email address: mailto:randers@usgs.gov / qualifier | |||||||||||||||
point in time: 12 May 2024
| |||||||||||||||
| Property / email address: mailto:randers@usgs.gov / qualifier | |||||||||||||||
| |||||||||||||||
| Property / email address: mailto:randers@usgs.gov / reference | |||||||||||||||
| Property / email address: mailto:randers@usgs.gov / reference | |||||||||||||||
| Property / is affiliated with | |||||||||||||||
| Property / is affiliated with: California Water Science Center / rank | |||||||||||||||
| Property / is affiliated with: California Water Science Center / qualifier | |||||||||||||||
| |||||||||||||||
| Property / is affiliated with: California Water Science Center / reference | |||||||||||||||
| Property / ORCID iD | |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / rank | |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / qualifier | |||||||||||||||
| |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / reference | |||||||||||||||
| Property / ORCID iD | |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / qualifier | |||||||||||||||
point in time: 30 January 2024
| |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / qualifier | |||||||||||||||
status code: 200 | |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / qualifier | |||||||||||||||
last update: 23 May 2024
| |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / qualifier | |||||||||||||||
retrieved: 23 May 2024
| |||||||||||||||
| Property / ORCID iD: 0000-0002-2363-9072 / reference | |||||||||||||||
| Property / official website | |||||||||||||||
| Property / official website: https://www.usgs.gov/staff-profiles/robert-anders / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / official website: https://www.usgs.gov/staff-profiles/robert-anders / qualifier | |||||||||||||||
retrieved: 13 September 2024
| |||||||||||||||
| Property / official website: https://www.usgs.gov/staff-profiles/robert-anders / qualifier | |||||||||||||||
status code: 200 | |||||||||||||||
| Property / official website: https://www.usgs.gov/staff-profiles/robert-anders / qualifier | |||||||||||||||
last update: 21 September 2024
| |||||||||||||||
| Property / employer | |||||||||||||||
| Property / employer: United States Geological Survey / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / employer: United States Geological Survey / qualifier | |||||||||||||||
point in time: 12 May 2024
| |||||||||||||||
| Property / employer: United States Geological Survey / reference | |||||||||||||||
| Property / is affiliated with | |||||||||||||||
| Property / is affiliated with: California Water Science Center / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / is affiliated with: California Water Science Center / qualifier | |||||||||||||||
point in time: 12 May 2024
| |||||||||||||||
| Property / is affiliated with: California Water Science Center / reference | |||||||||||||||
| Property / occupation | |||||||||||||||
| Property / occupation: hydrologist / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / occupation: hydrologist / qualifier | |||||||||||||||
point in time: 12 May 2024
| |||||||||||||||
| Property / occupation: hydrologist / reference | |||||||||||||||
| Property / manner of evaluation | |||||||||||||||
| Property / manner of evaluation: Research Grade Evaluation / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / manner of evaluation: Research Grade Evaluation / qualifier | |||||||||||||||
point in time: 30 January 2024
| |||||||||||||||
| Property / manner of evaluation: Research Grade Evaluation / reference | |||||||||||||||
| Property / OpenAlex ID | |||||||||||||||
| Property / OpenAlex ID: A5025711714 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / OpenAlex ID: A5025711714 / qualifier | |||||||||||||||
retrieved: 23 May 2024
| |||||||||||||||
| Property / OpenAlex ID: A5025711714 / qualifier | |||||||||||||||
last update: 23 May 2024
| |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Cancer Immunotherapy / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Cancer Immunotherapy / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Cancer Immunotherapy / qualifier | |||||||||||||||
prevalence: 194
| |||||||||||||||
| Property / knows about: Cancer Immunotherapy / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Immunobiology of Dendritic Cells / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Immunobiology of Dendritic Cells / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Immunobiology of Dendritic Cells / qualifier | |||||||||||||||
prevalence: 77
| |||||||||||||||
| Property / knows about: Immunobiology of Dendritic Cells / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Pancreatic Cancer Research and Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Pancreatic Cancer Research and Treatment / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Pancreatic Cancer Research and Treatment / qualifier | |||||||||||||||
prevalence: 74
| |||||||||||||||
| Property / knows about: Pancreatic Cancer Research and Treatment / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / qualifier | |||||||||||||||
prevalence: 68
| |||||||||||||||
| Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Molecular Characterization of Colorectal Cancer / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Molecular Characterization of Colorectal Cancer / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Molecular Characterization of Colorectal Cancer / qualifier | |||||||||||||||
prevalence: 50
| |||||||||||||||
| Property / knows about: Molecular Characterization of Colorectal Cancer / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Natural Killer Cells in Immunity / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Natural Killer Cells in Immunity / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Natural Killer Cells in Immunity / qualifier | |||||||||||||||
prevalence: 49
| |||||||||||||||
| Property / knows about: Natural Killer Cells in Immunity / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Hepatocellular Carcinoma / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Hepatocellular Carcinoma / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Hepatocellular Carcinoma / qualifier | |||||||||||||||
prevalence: 47
| |||||||||||||||
| Property / knows about: Hepatocellular Carcinoma / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Chimeric Antigen Receptor T Cell Therapy / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Chimeric Antigen Receptor T Cell Therapy / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Chimeric Antigen Receptor T Cell Therapy / qualifier | |||||||||||||||
prevalence: 43
| |||||||||||||||
| Property / knows about: Chimeric Antigen Receptor T Cell Therapy / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Advancements in Colorectal Cancer Research / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Advancements in Colorectal Cancer Research / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Advancements in Colorectal Cancer Research / qualifier | |||||||||||||||
prevalence: 42
| |||||||||||||||
| Property / knows about: Advancements in Colorectal Cancer Research / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Epidemiology and Management of NAFLD / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Epidemiology and Management of NAFLD / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Epidemiology and Management of NAFLD / qualifier | |||||||||||||||
prevalence: 41
| |||||||||||||||
| Property / knows about: Epidemiology and Management of NAFLD / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Cholangiocarcinoma / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Cholangiocarcinoma / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Cholangiocarcinoma / qualifier | |||||||||||||||
prevalence: 38
| |||||||||||||||
| Property / knows about: Cholangiocarcinoma / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Engineering Bacteria for Cancer Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Engineering Bacteria for Cancer Treatment / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Engineering Bacteria for Cancer Treatment / qualifier | |||||||||||||||
prevalence: 27
| |||||||||||||||
| Property / knows about: Engineering Bacteria for Cancer Treatment / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Radiomics in Medical Imaging Analysis / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Radiomics in Medical Imaging Analysis / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Radiomics in Medical Imaging Analysis / qualifier | |||||||||||||||
prevalence: 24
| |||||||||||||||
| Property / knows about: Radiomics in Medical Imaging Analysis / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Macrophage Activation and Polarization / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Macrophage Activation and Polarization / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Macrophage Activation and Polarization / qualifier | |||||||||||||||
prevalence: 19
| |||||||||||||||
| Property / knows about: Macrophage Activation and Polarization / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Mechanisms and Implications of Ferroptosis in Cancer / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Mechanisms and Implications of Ferroptosis in Cancer / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Mechanisms and Implications of Ferroptosis in Cancer / qualifier | |||||||||||||||
prevalence: 18
| |||||||||||||||
| Property / knows about: Mechanisms and Implications of Ferroptosis in Cancer / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Comprehensive Integration of Single-Cell Transcriptomic Data / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Comprehensive Integration of Single-Cell Transcriptomic Data / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Comprehensive Integration of Single-Cell Transcriptomic Data / qualifier | |||||||||||||||
prevalence: 17
| |||||||||||||||
| Property / knows about: Comprehensive Integration of Single-Cell Transcriptomic Data / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Role of Hippo Signaling Pathway in Mechanotransduction / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Role of Hippo Signaling Pathway in Mechanotransduction / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Role of Hippo Signaling Pathway in Mechanotransduction / qualifier | |||||||||||||||
prevalence: 17
| |||||||||||||||
| Property / knows about: Role of Hippo Signaling Pathway in Mechanotransduction / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Pathogenesis and Management of Biliary Atresia / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Pathogenesis and Management of Biliary Atresia / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Pathogenesis and Management of Biliary Atresia / qualifier | |||||||||||||||
prevalence: 17
| |||||||||||||||
| Property / knows about: Pathogenesis and Management of Biliary Atresia / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Role of STAT3 in Cancer Inflammation and Immunity / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Role of STAT3 in Cancer Inflammation and Immunity / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Role of STAT3 in Cancer Inflammation and Immunity / qualifier | |||||||||||||||
prevalence: 17
| |||||||||||||||
| Property / knows about: Role of STAT3 in Cancer Inflammation and Immunity / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: RNA Methylation and Modification in Gene Expression / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: RNA Methylation and Modification in Gene Expression / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: RNA Methylation and Modification in Gene Expression / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
| Property / knows about: RNA Methylation and Modification in Gene Expression / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Diversity and Function of Gut Microbiome / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Diversity and Function of Gut Microbiome / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Diversity and Function of Gut Microbiome / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
| Property / knows about: Diversity and Function of Gut Microbiome / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Diagnosis and Management of Biliary Tract Disorders / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Diagnosis and Management of Biliary Tract Disorders / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Diagnosis and Management of Biliary Tract Disorders / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
| Property / knows about: Diagnosis and Management of Biliary Tract Disorders / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Mechanisms and Treatment of Liver Fibrosis / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Mechanisms and Treatment of Liver Fibrosis / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Mechanisms and Treatment of Liver Fibrosis / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
| Property / knows about: Mechanisms and Treatment of Liver Fibrosis / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Cell Mechanics and Extracellular Matrix Interactions / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Cell Mechanics and Extracellular Matrix Interactions / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Cell Mechanics and Extracellular Matrix Interactions / qualifier | |||||||||||||||
prevalence: 14
| |||||||||||||||
| Property / knows about: Cell Mechanics and Extracellular Matrix Interactions / reference | |||||||||||||||
| Property / knows about | |||||||||||||||
| Property / knows about: Clostridium difficile Infection and Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / knows about: Clostridium difficile Infection and Treatment / qualifier | |||||||||||||||
point in time: 23 May 2024
| |||||||||||||||
| Property / knows about: Clostridium difficile Infection and Treatment / qualifier | |||||||||||||||
prevalence: 14
| |||||||||||||||
| Property / knows about: Clostridium difficile Infection and Treatment / reference | |||||||||||||||
Latest revision as of 19:53, 22 September 2024
Research Hydrologist with the California Water Science Center
- Robert Anders
- Robert Albert Anders
- R. Anders
- Robert A. Anders
- R. A. Anders
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Robert Anders |
Research Hydrologist with the California Water Science Center |
|
Statements
12 May 2024
12 May 2024
12 May 2024
12 May 2024
0 references
30 January 2024
23 May 2024
194
1 reference
23 May 2024
77
1 reference
23 May 2024
74
1 reference
1 reference
1 reference
23 May 2024
49
1 reference
23 May 2024
47
1 reference
23 May 2024
43
1 reference
23 May 2024
42
1 reference
23 May 2024
41
1 reference
23 May 2024
38
1 reference
23 May 2024
27
1 reference
23 May 2024
24
1 reference
23 May 2024
19
1 reference
1 reference
23 May 2024
17
1 reference
1 reference
1 reference
1 reference
1 reference
23 May 2024
15
1 reference
1 reference
23 May 2024
15
1 reference
1 reference
23 May 2024
14
1 reference
